0000000001122914

AUTHOR

Herbert Lochs

showing 2 related works from this author

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

2006

1. Aliment Pharmacol Ther. 2006 Apr 15;23(8):1117-25. Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Operative Unit of Gastroenterology, St Camillo-Forlanini Hospital, Rome, Italy. prantera@tin.it BACKGROUND: Clinicians often employ antibiotics in Crohn's disease. Rifaximin is active against bacteria frequently found in the intestinal mucosa of Crohn's disease patients. AIM: To evaluate the difference in efficacy between once and twice/daily oral administration of rifaximin and placebo in the treatment of active Crohn's …

AdultMalemedicine.medical_specialtyPlacebo-controlled studyCIPROFLOXACINPlaceboGastroenterologyInflammatory bowel diseaseDrug Administration ScheduleRifaximinPlaceboschemistry.chemical_compoundCrohn DiseaseDouble-Blind MethodIntestinal mucosaINFLAMMATORY-BOWEL-DISEASE C-REACTIVE PROTEIN ULCERATIVE-COLITIS METRONIDAZOLE CIPROFLOXACIN MANAGEMENT RECURRENCE DIARRHEA ANTIBODY MODERATEInternal medicinemedicineMANAGEMENTHumansPharmacology (medical)RECURRENCEAntibacterial agentCrohn's diseaseChi-Square DistributionHepatologybusiness.industryGastroenterologyMiddle Agedmedicine.diseaseRifamycinsUlcerative colitisDIARRHEAC-REACTIVE PROTEINAnti-Bacterial AgentsSurgeryRifaximinTreatment OutcomechemistryULCERATIVE-COLITISANTIBODYMETRONIDAZOLEAcute Diseaserifaximin.crohn's diseaseMODERATEFemalebusinessINFLAMMATORY-BOWEL-DISEASE
researchProduct

Beclomethasone dipropionate in Crohn's ileitis: A randomised, double-blind trial.

2011

Abstract Background Steroids, the mainstay of Crohn's disease treatment, have been associated with systemic side effects. Aim To evaluate the efficacy and tolerability of beclomethasone dipropionate for maintaining remission induced by a short course of systemic steroids in patients with Crohn's ileitis with or without right colonic involvement. Methods Patients (n = 84) with active Crohn's disease who achieved remission during a 2-week prednisone run-in period were randomised to receive beclomethasone dipropionate for 24 weeks or continue prednisone for a further 2 weeks followed by placebo for 22 weeks. The primary outcome was relapse rate (Crohn's Disease Activity Index score > 150 and a…

AdultMalemedicine.medical_specialtySettore MED/09 - Medicina InternaRemissionKaplan-Meier EstimateBeclomethasone dipropionate Crohn's disease RemissionPlaceboGastroenterologyDrug Administration ScheduleMedication Adherencelaw.inventionDouble blindCrohn DiseaseDouble-Blind MethodRandomized controlled triallawPrednisoneInternal medicineSecondary PreventionmedicineHumansIleitisAdverse effectGlucocorticoidsAgedCrohn's diseaseHepatologybusiness.industryRemission InductionBeclomethasoneGastroenterologyBeclomethasone dipropionate Crohn's ileitis:.Middle Agedmedicine.diseaseSurgeryBeclomethasone dipropionateCrohn's diseaseTreatment OutcomeTolerabilityPrednisoneFemaleTablets Enteric-Coatedbusinessmedicine.drug
researchProduct